Renfu Medicine: The Injection of Methoxamine Hydrochloride has obtained the drug registration certificate.

Renfu Pharmaceuticals announced that its holding subsidiary Yichang Renfu Pharmaceuticals recently received the "Drug Registration Certificate" issued by the National Medical Products Administration for the approved epinephrine bitartrate injection. This drug is used for blood pressure control in certain cases of acute hypotension, as well as for the auxiliary treatment of cardiac arrest and severe hypotension. The national sales for the year 2024 is expected to be around 2.1 billion yuan. This approval marks the company's eligibility to sell this drug in the domestic market and further enriches its product line.